Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Perindopril tert-butylamine is an **angiotensin-converting enzyme (ACE) inhibitor** used primarily to treat hypertension (high blood pressure), heart failure, and to reduce cardiovascular risk in patients with stable coronary artery disease. As a prodrug, it is converted in the body to the active metabolite, perindoprilat, which inhibits ACE, reducing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This results in vasodilation and decreased blood pressure. Additional effects include decreased aldosterone secretion and inhibition of kininase II, which may increase bradykinin levels. It is often used as monotherapy or in combination with other drugs like indapamide (a thiazide-like diuretic) or amlodipine (a calcium channel blocker) to enhance antihypertensive effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on perindopril tert-butylamine.